Ron Levy, MD (Emeritus Board Member), and colleagues at Stanford University School of Medicine, Stanford, reported the success of an injectable "vaccine" delivered directly to tumors. The vaccine combines two key agents, a short piece of DNA called CpG oligonucleotide with an antibody that binds to OX40, thus activating immune T cells to fight cancer cells. In mice, they found that it could eliminate all traces of the injected tumors, including untreated metastases in the same animal. A human clinical trial in low-grade lymphoma patients is currently underway. The study was published in the journal Science Translational Medicine.